
CellaVision
164
SEK
-0,24 %
1.489 følger denne virksomhed
CEVI
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Finansielt overblik og estimater
Ownership
-0,24%
-15,46%
-24,6%
-27,11%
-39,59%
-31,38%
-47,67%
-28,07%
+951,28%
CellaVision operates in the medical technology industry and focuses on the development and manufacture of systems for digital blood analysis. The company's products are aimed at healthcare institutions and laboratories. The business is global, with a primary presence in Europe, North America and Asia. CellaVision was founded in 1994 and is headquartered in Lund, Sweden.
Læs mereMarkedsværdi
3,91 mia. SEK
Aktieomsætning
3,67 mio. SEK
Omsætning
723,22 mio.
EBIT %
24,57 %
P/E
27,8
Udbytteafkast, %
1,37 %
Finanskalender
29.4
2025
Delårsrapport Q1'25
6.5
2025
Generalforsamling '25
7.5
2025
Årligt udbytte
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper

Mixed Regional Performance Sales Peak in APAC
Modular Finance IR Consensus: CellaVision – Consensus estimates Q4 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Invitation to Presentation of the CellaVision Year-end Report for 2024 on February 6, at 11:00 CET
Nomination Committee for the CellaVision Annual General Meeting 2025
Redeye: Cellavision Q3’2024 - Underlying momentum intact

CellaVision, Audiocast with teleconference, Q3'24
Strong Sales in EMEA Amid Market Uncertainties in the US
Invitation to Presentation of the CellaVision Report for the Third Quarter 2024 on October 24, at 11:00 CEST
Redeye: Cellavision Q2 - Mostly in line with some minor issues

CellaVision, Audiocast with teleconference, Q2'24
Solid Quarter and Growth in APAC
Invitation to Presentation of the CellaVision Report for the Second Quarter 2024 on July 19, at 11:00 CEST
Bulletin from the Annual General Meeting of CellaVision AB (publ)
Redeye: Cellavision - Trend is still their friend
